Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283873 | 0.98 | CYP1A2 (0.46) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL25192919 | 0.94 | CYP1A2 (0.43) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL6519311 | 0.91 | KDM5A (0.51) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL384147 | 0.91 | KDM5A (0.50) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL6521504 | 0.91 | KDM5A (0.51) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL9089300 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL9061840 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL19612642 | 0.90 | KDM5A (0.53) | CYP1A2HPGDKDM5APHF8KDM2A | |
| SCHEMBL279341 | 0.86 | HPGD (0.50) | HPGDP2RX7ALDH1A1TP53EPHX1 | |
| SCHEMBL1595294 | 0.84 | HPGD (0.53) | CYP1A2HPGDP2RX7ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119403840-A | Photocurable composition, method for producing cured film, solid-state imaging element, image display device, and radical polymerization initiator | 富士胶片株式会社 | 2025-02-07 | — | — | CN | disclosed |
| CN-119241520-A | Oxime ester photoinitiator and photopolymerization composition | 武汉尚赛光电科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024043108-A1 | PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED FILM, FILM, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND RADICAL POLYMERIZATION INITIATOR | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-9637444-B2 | Bisoxime ester photoinitiator and preparation method and use thereof | CHANGZHOU TRONLY ADVANCED ELECTRONIC MATERIALS CO., LTD. (CN) | 2017-05-02 | — | — | US | disclosed |
| US-20160376226-A1 | Bisoxime Ester Photoinitiator and Preparation Method and Use Thereof | CHANGZHOU TRONLY NEW ELECTRONIC MATERIALS CO., LTD. (CN) | 2016-12-29 | — | — | US | disclosed |
| CN-103833872-B | A kind of two oxime ester lightlike initiating agent and its preparation method and application | CHANGZHOU QIANGLI ADVANCED ELECTRIC MATERIALS CO., LTD. (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-103833872-A | Di-oxime ester photoinitiator as well as preparation method and application thereof | CHANGZHOU TRONLY ADVANCED ELECTRONIC MATERIALS CO LTD | 2014-06-04 | — | — | CN | disclosed |
| CN-1149869-A | Substituted sulfonamides as selective beta3 agonists for treatment of diabetes and obesity | MERCK & CO LTD (US) | 1997-05-14 | — | — | CN | disclosed |
| EP-0757674-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5561142-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-10-01 | — | — | US | disclosed |
| US-5541197-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376226-A1 | Bisoxime Ester Photoinitiator and Preparation Method and Use Thereof | PPOX, CYP51A1, FHIT | CYP1A2 9/4885HPGD 1741/4885KDM5A 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.